Literature DB >> 10448131

Fenretinide and its relation to cancer.

E Ulukaya1, E J Wood.   

Abstract

Retinoids, natural or synthetic substances which have vitamin A activity, have a well-known reputation for their antitumour and differention-inducing activity in vitro and in vivo. More than 1500 retinoids have been tested so far but very few of them have been entered into clinical trials because of their side-effects. All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid. In addition, fenretinide has been shown to induce cell death (apoptosis) even in ATRA-resistant cell lines. Although the mechanism by which fenretinide acts is not entirely known it is considered to be a promising drug and seems to induce apoptosis via different pathway(s) from classical retinoids. In this review, we discuss possible mechanisms of fenretinide action and summarize results of clinical trials. Copyright 1999 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448131     DOI: 10.1053/ctrv.1999.0127

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  18 in total

1.  Impact of 4HPR on the expression of E-Cad in human bladder transitional epithelial cancer cells T24.

Authors:  Eyou Wang; Jun Li; Guohua Yang; Shan Zhong; Tongzu Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-04-20

Review 2.  Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

Authors:  Jason P Cooper; C Patrick Reynolds; Hwangeui Cho; Min H Kang
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-21

3.  Fenretinide inhibits vitamin A formation from β-carotene and regulates carotenoid levels in mice.

Authors:  Anthony P Miller; Molly Black; Jaume Amengual
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2021-11-04       Impact factor: 4.698

Review 4.  Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule.

Authors:  Rosa Luisa Potenza; Pietro Lodeserto; Isabella Orienti
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

5.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

6.  Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Authors:  Vivian R Ruvolo; Kul B Karanjeet; Todd F Schuster; Rhoderick Brown; Yibin Deng; Edward Hinchcliffe; Peter P Ruvolo
Journal:  J Signal Transduct       Date:  2010-01-01

7.  Differential and isomer-specific modulation of vitamin A transport and the catalytic activities of the RBP receptor by retinoids.

Authors:  Riki Kawaguchi; Ming Zhong; Miki Kassai; Mariam Ter-Stepanian; Hui Sun
Journal:  J Membr Biol       Date:  2013-06-29       Impact factor: 1.843

Review 8.  Immune cells in the tumour: new routes of retinoids for chemoprevention and chemotherapeutics.

Authors:  Li Jiang; Rong Dong; Meidan Ying; Qiaojun He; Ji Cao; Bo Yang
Journal:  Br J Pharmacol       Date:  2018-11-08       Impact factor: 8.739

Review 9.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

10.  Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity.

Authors:  F Rehman; P Shanmugasundaram; M P Schrey
Journal:  Br J Cancer       Date:  2004-11-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.